US EditionEli Lilly’s weight loss pill orforglipron clears its latest trial, paving way for approval
Eli Lilly's orforglipron pill led to a 10.5% average weight loss and a 1.8% reduction in blood sugar over 72 weeks in patients with obesity and Type 2 diabetes, meeting key trial endpoints.
- Eli Lilly announced on Tuesday that its weight loss pill orforglipron helped obese patients with Type 2 diabetes lose up to 10.5% of their body weight in a late-stage trial.
- The ATTAIN-2 trial involved over 1,600 participants who started at low doses and gradually increased at four-week intervals to one of three target doses or placebo.
- More than half the patients on the highest dose lost at least 10% of their weight, 28.4% lost 15% or more, and the pill also lowered A1C by 1.3% to 1.8%.
- Kenneth Custer, Lilly's head of cardiometabolic health, stated that based on the encouraging results, the company is promptly preparing to seek regulatory approval worldwide to address the needs of waiting patients.
- The trial showed mostly mild-to-moderate gastrointestinal side effects and clears the way for Lilly to file for global approval of the pill within this year.
29 Articles
29 Articles
Eli Lilly’s Obesity Pill Breakthrough Shakes Up $150 Billion Weight-Loss Race
Key Points in This Article: Eli Lilly’s (LLY) Zepbound has outshone Novo Nordisk’s Wegovy, achieving superior weight-loss results in clinical trials. The weight-loss drug market is highly competitive, driven by the success of injectable GLP-1 drugs like Ozempic. An oral weight-loss pill is the industry’s ultimate goal, and Lilly’s latest announcement may have redefined the race. Nvidia made early investors rich, but there is a new class of ‘…
Eli Lilly Captures Major Lead in Weight-Loss Pill Race
Eli Lilly tipped the scales Tuesday, announcing a successful trial of its weight-loss pill that led stock in competitors to shed some muscle mass. The pharmaceutical giant now has the trial data in hand to seek approval from regulators around the world, meaning its pill orforglipron could soon swallow a large chunk of the highly lucrative GLP-1 drug market. No More Needling GLP-1 drugs, which reduce a person’s appetite by suppressing gut hormone…
Lilly's experimental drug shows positive results for weight loss in diabetes patients
LOS ANGELES, Aug. 26 (Xinhua) -- U.S. pharmaceutical company Lilly announced Tuesday that its experimental oral GLP-1 receptor agonist, orforglipron, achieved positive results in a Phase 3 trial targeting adults with overweight and type 2 diabetes. Read full story
Coverage Details
Bias Distribution
- 70% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
